Thyrocare Technologies Limited — PPTs, 23-01-2025: Investor Presentation

Thyrocare delivered a robust performance in Q3 FY25, achieving a consolidated revenue of ₹166 Cr, marking a 23% year-on-year growth. Key drivers included a 24% increase in franchise revenue and a 23% rise in partnership revenue. The company's expanding franchise network now boasts over 9,100 active franchisees, and patient numbers climbed to 3.9 million, up 13% from the previous year.

Operational enhancements have led to an impressive 98% of samples processed in NABL-accredited labs. Noteworthy strategic initiatives included the acquisition of Polo Labs and Vimta Labs, expanding Thyrocare's footprint in northern and southern India, respectively. The company also enhanced its ECG at Home services, now active in over 1,000 pincodes.

Financial metrics were strong, with normalized EBITDA rising 42% and profit after tax increasing by 30% year-to-date. Overall, the outlook remains positive, supported by ongoing strategic expansions and solid financial growth, which positions Thyrocare well for future performance.